Table 1 Clinical half-lives, charge parameters and FcRn-binding capacities of ABTs and their cognate Ags.

From: Biophysical differences in IgG1 Fc-based therapeutics relate to their cellular handling, interaction with FcRn and plasma half-life

  

ABM charge

AIR charge

Ag charge

FcRn binding

ABT

Clinical t1/2 (days)a

pH 5.5

pH 7.4

pH 5.5

pH 7.4

pH 5.5

pH 7.4

Ka(104/Ms)

Kd (10−2/s

KD (nM)

Elution peak pH

Infliximab

8–10

3.1

−1.6

3.7

1.3

TNF-α

3.5

0.2

310

7.15

Adalimumab

14 (10–20)

5.2

2.2

2.0

1.1

−6.1

−15.4

4.2

0.1

430

7.21

Etanercept

2–4

3.2

0.8

3.1

3.0

  

3.1

0.1

380

6.88

Aflibercept

5–6

10.8

4.3

5.9

4.2

VEGF

3.0

0.1

350

7.01

Bevacizumab

20 (10–50)

5.0

1.4

−0.3

−2.7

−2.1

−10.0

3.2

0.1

380

7.20

  1. aThe stated clinical plasma half-lives of ABTs were retrieved from FDA package inserts. For bevacizumab, the stated clinical half-life of 20 days refers to a large, clinical study following intravenous injection60.
Back to article page